Table 3.
HIV treatment outcomes in patients with MDR-TB and non MDR-TB in the SAPiT trial
| MDR-TB patients N=23 |
All patients both treatment arms N=489 |
|||||
|---|---|---|---|---|---|---|
| Combined Integrated treatment arm |
Sequential treatment arm |
p- value |
MDR-TB | non MDR- TB |
p- value |
|
|
Viral load < 400 copies/ml | ||||||
| 12 months after randomization: n/N (%) |
7/9 (78) | 4/4 (100) | 1.00 | 11/13 (85) | 277/325 (85) |
1.00 |
| 6 months after initiation of anti- retroviral therapy: n/N (%) |
5/6 (83) | 4/4 (100) | 1.00 | 9/10 (90) | 211/239 (88) |
1.00 |
|
Mean increase in CD4+ count from baseline | ||||||
|
12 months after randomization | ||||||
| N | 9 | 4 | 13 | 327 | ||
| Mean CD4+ cell count increase in cells/mm3 (95% CI) |
108.0 (−30 – 246) |
89.8 (−183 – 362) |
0.55 | 102.4 (−0.1 – 204.9) |
132.4 (118.6 – 146.2) |
0.82 |
|
6 months after initiation of antiretroviral therapy | ||||||
| N | 6 | 4 | 10 | 240 | ||
| Mean CD4+ cell count increase in cells/mm3 (95% CI) |
122.5 (36.9 – 208.1) |
131.8 (−71.4 – 334.9) |
0.59 | 126.2 (57.8 – 194.6) |
117.9 (102.7 – 133.2) |
0.59 |
MDR-TB: Multidrug resistant tuberculosis
CI: Confidence interval